Who is sponsoring NCT01850160?

NCT01850160 is sponsored by Farma de Colombia SA.

What drugs are being tested in NCT01850160?

Interventions in NCT01850160: GROUP A: Valsartan plus Chlorthalidone, GROUP B: Valsartan, GROUP C: Chlorthalidone.

What condition does NCT01850160 study?

NCT01850160 studies Hypertension.

Is NCT01850160 still recruiting?

NCT01850160 is currently completed. Last updated 25 January 2016.

Last reviewed 2016-01-25 · How we verify

NCT01850160

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial

Completed Phase 3 Last updated 25 January 2016

What this trial tests

Phase 3 trial testing GROUP A: Valsartan plus Chlorthalidone in Hypertension in 124 participants. Completed in 1 May 2015.

Timeline

1 April 2013

Primary endpoint
1 March 2015

1 May 2015

Quick facts

Lead sponsor	Farma de Colombia SA
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	124
Start date	1 April 2013
Primary completion	1 March 2015
Estimated completion	1 May 2015
Sites	8 locations across Colombia, Ecuador

Drugs / interventions tested

GROUP A: Valsartan plus Chlorthalidone — full drug profile →
GROUP B: Valsartan — full drug profile →
GROUP C: Chlorthalidone — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Farma de Colombia SA — full company profile →

Who can join

Adults 18 to 70, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and Efficacy of the fixed-dose combination treatment with Valsartan plus Chlorthalidone
Time frame: 12 weeks
Efficacy and safety of a fixed-dose combination treatment of Valsartan plus Chlorthalidone Vs Valsartan or Chlorthalidone alone in the treatment of patients with arterial hypertension

Sponsor's own description

This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of adult patients with diagnosis of arterial hypertension.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study.
Manzur F, Rico A, Romero JD, Rodriguez-Martinez CE. · · 2018 · cited 2× · PMID 30202211 · DOI 10.1177/1179546818796482

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01850160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Farma de Colombia SA
Last refreshed: 25 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01850160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing